In this paper, a new approach in human identification is investigated. For this purpose, a standard 12-lead electrocardiogram (ECG) recorded during rest is used. Selected features extracted from the ECG are used to identify a person in a predetermined group. Multivariate analysis is used for the identification task. Experiments show that it is possible to identify a person by features extracted from one lead only. Hence, only three electrodes have to be attached on the person to be identified. This makes the method applicable without too much effort.
Background/Aim: The optimal treatment sequencing for asymptomatic de novo metastatic rectal cancer is unclear. The aim of this study was to investigate the role of upfront radiotherapy, with or without chemotherapy on risk for local complications, in patients with asymptomatic advanced metastatic rectal cancer treated with palliative intention. Patients and Methods: All patients with de novo metastatic rectal cancer diagnosed between January 2008 and December 2017 in two healthcare regions in Sweden (Örebro län, Sörmland) were identified and data were extracted from electronic medical records. Patients were divided into 3 groups based on treatment sequence: upfront radiotherapy, upfront chemotherapy, and only palliative surgery. Results: In total, 102 patients were included in the study cohort, 30 patients in upfront radiotherapy group, 54 in upfront chemotherapy, and 18 in only palliative surgery group. Patients with only upfront CT [odds ratio (OR)= 5.10; 95% confidence interval (CI)=1. 24-20.91, p=0.024] had a higher risk to suffer from a local complication compared to those who received upfront radiotherapy. Cause-specific Cox regression analysis among patients who received oncological therapy revealed that female patients [cause-specific hazard ratio (csHR)=3.61; 95% confidence interval (CI)=1.67-7.81] and upfront chemotherapy [csHR=1.85; 95% CI=1.11-3.77] were associated with increased cumulative incidence of local complication over time, whereas primary surgery with ostomy or stent with lower risk [csHR=0.45; 95% CI=0.21-0.99]. Conclusion: Patients who received upfront radiotherapy, with or without chemotherapy, had fewer local complications due to primary tumor compared to patients who only received chemotherapy. This could indicate that radiotherapy to the primary tumor could be discussed with the patients as a first treatment option for asymptomatic metastatic rectal cancer to prevent local complications later during the disease.Approximately 20% of patients with rectal cancer are presented with de novo metastatic disease and receive treatment with palliative intention (1). These patients are at increased risk for intestinal complications including bowel obstruction, rectal bleeding, pelvic pain, fistula formation, and perforation that can impair quality of life of the patients (1).In patients with symptomatic advanced rectal cancer, the treatment strategy includes an upfront local therapeutic approach with either surgery or radiotherapy to relief local symptoms. Considering the negative effect of colostomy following surgery in quality of life (2), alternative local treatment strategies have been tested to avoid surgery. In fact, several prospective phase II studies have found that upfront radiotherapy, with or without chemotherapy, offers a symptom control rate of >85% which is often long-lasting (3-5).The treatment approach in patients with asymptomatic advanced rectal cancer is, however, more controversial. Traditionally, prophylactic tumor resection has been considered as the first step on the can...
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.